The regulatory effects of extracellular vesicles derived from adipose stem cells on tumor biological activity.
Qi Z., Zhang X., Liu M., Li X., Wang W., Cui X.
Narrative Review, published in J Physiol Biochem (2026) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Narrative Review
- Journal
- J Physiol Biochem (2026)
- Country
- Spain
- Reported sample size
- —
- Source database
- PubMed
- PMID
- 42397518
- DOI
- 10.1007/s13105-026-01202-1
Abstract (original English)
The field of malignant tumor diagnosis and treatment urgently requires innovative research perspectives to overcome the existing limitations. Extracellular vesicles (EVs) are crucial mediators of intercellular communication, offering novel avenues for regulating tumors. Among these, extracellular vesicles derived from adipose-derived stem cells (ADSC-EVs) have garnered significant attention because of their exceptional stability, safety profile, and ease of storage and transportation. Here, we first elucidate the biological foundation of ADSC-EVs, delineating their biogenesis pathway characterized by the "early endosome-multivesicular body-extracellular release" process, and highlight the heterogeneity of their molecular cargo. This cargo includes 148 regulatory microRNAs (such as the let-7 family and miR-122), 1,466 functional proteins, and various lipid molecules, thereby underpinning its multifunctional regulatory potential. Mechanistically, the dual role of ADSC-EVs is emphasized: on one hand, they can activate signaling pathways, such as PI3K/AKT, or modulate metabolic reprogramming to promote tumor proliferation; on the other hand, they exert tumor-suppressive effects by delivering specific microRNAs (e.g., miR-503-3p) and remodeling the tumor immune microenvironment to influence tumor progression. From an application standpoint, the tripartite value of ADSC-EVs is unders
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.